Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Quote form Andrew Salzman, check out interview

<< Previous

Bullboard Posts

Next >>

Comment by Moonshiner592on Apr 11, 2021 11:00pm

234 Views

Post# 32975539

RE:Quote form Andrew Salzman, check out interview

Dude51 wrote: Claritas Investors website

"Claritas really has, in my judgment, a fantastic platform technology. It's novel, and it's a leader in the field of nitric oxide. All the data to date have shown efficacy in models of sepsis and pneumonia, and also, as a nitric oxide donor, there will be efficacy against the COVID virus. So, Claritas is beautifully positioned right now to exploit this technology to its fullest extent."

GLTA

Love the sound of this!

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario